[Asia Economy Reporter Hyunseok Yoo] Olix, a company developing next-generation nucleic acid therapeutics based on RNA interference technology, announced on the 25th that it is participating in the Nucleic Acid Therapies conference hosted by the Cold Spring Harbor Laboratory (CSHL) in the United States from the 24th to the 26th, presenting poster presentations.
At this conference, Olix will present to experts in the field of nucleic acid therapeutics through poster presentations on ▲ its proprietary self-delivering asymmetric siRNA (cp-asiRNA) technology ▲ excellent hepatocyte delivery and efficacy test data of the liver disease siRNA therapeutic platform (GalNAc-asiRNA) confirmed in animal models ▲ research results of ocular disease therapeutics OLX301A and OLX301D, which have further improved intracellular delivery compared to existing treatments ▲ efficacy test results of hair loss therapeutics.
Lee Dong-gi, CEO of Olix, stated, “Multiple ongoing therapeutic research and development projects are progressing as planned. Based on excellent research outcomes, we will spare no effort or support to enable our pipelines to quickly enter clinical trials, and we will actively engage in technology transfer discussions to enhance corporate value.”
CSHL is a world-class life sciences research institute and educational institution located in New York State, USA. It has produced eight Nobel Prize winners in Physiology or Medicine. It hosts global conferences annually on 25 to 30 related topics. This conference is sponsored by global big pharma companies such as Merck, Pfizer, Bayer, and Genentech, and is being held virtually due to COVID-19.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
